The VP, Finance & Accounting of Lexicon Pharmaceuticals (NASDAQ: LXRX) is Buying Shares

By Carrie Williams

Yesterday, the VP, Finance & Accounting of Lexicon Pharmaceuticals (LXRXResearch Report), James Tessmer, bought shares of LXRX for $11.4K.

Following this transaction James Tessmer’s holding in the company was increased by 29.97% to a total of $52.04K. In addition to James Tessmer, one other LXRX executive reported Buy trades in the last month.

See today’s analyst top recommended stocks >>

Currently, Lexicon Pharmaceuticals has an average volume of 3.31M.

Based on 4 analyst ratings, the analyst consensus is Moderate Buy with an average price target of $10.00, reflecting a 733.3% upside.

Company insider trades’ information is brought to you by the DailyInsider, a proprietary algorithm that analyzes insider trading activity to detect the most attractive trading opportunities. To subscribe to the DailyInsider visit this page.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Lexicon Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. It drug candidates include XERMELO, Sotagliflozin, LX2761, and LX9211. The company was founded by Brian P. Zambrowicz and Arthur T. Sands on July 7, 1995 and is headquartered in The Woodlands, TX.